Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The low affinity immunoglobulin gamma Fc region receptor III (FcγRIII) is a cell surface receptor that binds the Fc region of IgG antibodies with low to intermediate affinity, primarily recognizing complexed or aggregated IgG. It exists in two main forms: transmembrane FcγRIIIa (on NK cells, macrophages, monocytes) associated with signaling adapters like the γ-chain for ADCC and cytokine production, and GPI-anchored FcγRIIIb (on neutrophils). It mediates immune effector functions including immune complex clearance, NK cell degranulation, and inflammation modulation. Structural studies show conserved hinge binding similar to other FcγRs but unique features in high-affinity variants; polymorphisms influence binding and disease susceptibility.
Binding to IgG Fc region triggers ITAM-dependent signaling via associated γ-chain or CD247, leading to phosphorylation, PI3K activation, calcium influx, cytokine release, and cytotoxicity; low-affinity binding to monomeric or complexed IgG
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor III (FcγRIII).